Nitric oxide in immune thrombocytopenic purpura

Hematology

Volumn 14, Issue 1, 2009, Pages 59-62

  Thachil, Jecko ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Immune thrombocytopenia; Nitric oxide; Pathophysiology

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN; NITRIC OXIDE; RHESUS D ANTIBODY; RITUXIMAB; STEROID;

ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CD4+ T LYMPHOCYTE; CEREBROVASCULAR ACCIDENT; FATIGUE; HEART INFARCTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEGAKARYOCYTE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; TH1 CELL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; VASOCONSTRICTION; VEIN THROMBOSIS; METABOLISM;

HUMANS; NITRIC OXIDE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 64949157090     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X385151     Document Type: Article

References (27)

1. Patel SR, Hartwig JH, Italiano JE, Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005; 115: 3348-3354.
2. Battinelli E, Loscalzo J. Nitric oxide induces apoptosis in megakaryocytic cell hues. Blood 2000; 95: 3451-3459.
3. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Nad Acad Sci USA 2001; 98: 14458-14463.
4. Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895
5. Bussel JB, Cheng G, Saleb MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
6. Musaji A, Cormont F, Thirion G, Cambiaso CL, Coutelier JP. Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses. Blood 2004; 104: 2102-2106.
7. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferongamma-induced nitric oxide synthase. Science 1993; 261: 1445-1448.
8. Pierrot-Deseilligny Despujol C, Micliel M, Khellaf M et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008; 142: 638-643.
9. Delgado Alves J, Mason LJ, Ames: PR et al. Antiphospholipid antibodies are associated with enhaneda oxidative stress, decreased plasma nitric oxide and paraoxonase activity in art experimental mouse model. Rheumatology (Oxford) 2005; 44: 1238-1244.
10. Kline ER, Kleinhenz DJ, Liang B et al. Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reiersed by glutathione restorzion. Am J Physiol Heart Circ Physiol 2008; 294 H2792-H2804.
11. Gobert AP, McGee DJ, Akhtar M et al. Helicobacter pylori arginase inhibits nitric, oxide production by eukaryotir cells: A strategy for bacteria. survival. Proc Natl Acad Sci USA 2001; 98: 13844-13849.
12. Ogawara H, Handa, H, Morita K et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 71 283-288.
13. Panitsas FP, Theodoropoulou M, Kouraklis A et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103: 2645-2647.
14. Wei XQ, Charles IG, Smith A et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-411.
15. James SL, Cheever AW, Caspar P, Wynn TA. Inducible nitric oxide synthase-deficient n-&e develop enhanced type 1 cytokine-associated cellular and humoral immune responses after vaccination with attenuated Schistosoma mansoni cercariae but display partially reduced resistance. Infect Immun 1998; 66: 3510-3518.
16. Huang FP, Niedbala W, Wei XQ et al. Nitric ox!Ue regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol 1998; 28: 4062-4070.
17. Cappellini MD. Coagulation in the pathophysiology of hemolytic anemias. Hematology 2007; 2007: 74-78.
18. Taddei S, Virdis A, Ghiadoni L et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001; 38: 274-279.
19. Goubareva I, Gkaliagkousi E, Shah A, Queen L, Ritter J, Ferro A. Age decreases nitric oxide synthesis and responsiveness in human, platelets and increases formation of monocyte-platelet aggregates. Cardiovasc Res 2007; 75: 793-802.
20. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001; 81: 209-237.
21. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293: 1653-1662.
22. Aledort LM, Hayward CP, Chen MG et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts. Am J Hematol 2004; 76: 205-213.
23. 2+ mobilization and von Willebrand factor secretion, and increases nitric oxide release in human endothelial cells. Thromb Haemost 2003; 90: 1046-1053.
24. Stasi R, Del Poeta G, Stipa E et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
25. Kumpel BM, Elson CJ. Mechanism of anti-D-mediated suppression - a paradox awaiting resolution. Trends Immunol 2001; 22: 26-31.
26. Semple JW, Allen, D, Rutherford M, et al. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol 2002; 69: 225-227.
27. Kilbourn RG, Gross SS, Jubran A et al. NG-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87: 3629-3632.